Immediately following the 2006 midterm elections, when the Democrats last gained control of the House, three of the five worst-performing non-leveraged ETFs were healthcare funds, including XBI.

XBI is up more than 6% over the past week, perhaps indicating that this year, biotech investors were comfortable with the Democrats seizing control of the House.

LABU’s bearish counterpart is the Direxion Daily S&P Biotech Bear 3X Shares (NYSEArca: LABD). That ETF tries to deliver triple the daily inverse returns of the S&P Biotechnology Select Industry Index. That index is an equal-weight benchmark, meaning it leans toward mid- and small-cap biotech names.

For more on leveraged and inverse ETFs, please visit our Leveraged and Inverse Channel.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.